Drug Profile
BMS 687681 - Bristol-Myers Squibb
Alternative Names: BMS-687681; CCR2/5 antagonist - Bristol-Myers Squibb; CCR2/5 dual antagonistLatest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Immunological disorders
Most Recent Events
- 29 Dec 2022 Discontinued - Phase-I for Cancer in USA (unspecified route) (Bristol-Myers Squibb pipeline, December 2022)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Cancer in USA
- 21 Apr 2018 Pharmacodynamics data from a preclinical studies in Cancer presented at the at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)